Fig. 3

Hazard ratios* for a) hospitalized infections† and b) opportunistic infections in abatacept versus other b/tsDMARD initiators. Similar risk of TB was observed among abatacept and other b/tsDMARDs initiators in the MarketScan (HR [95% CI] 1.93 [0.45–8.32]) and PharMetrics (1.73 [0.17–17.63]) databases. It was not possible to analyze TB as an outcome in the Optum database because there were no events in the abatacept group and only two in the other b/tsDMARDs group. A meta-analysis of the outcome of TB was not performed due to low numbers. *Error bars represent 95% CIs. †Data represent hospitalizations associated with an infection as the primary diagnosis (one ICD-9-CM code). b/tsDMARDs, biologic or targeted synthetic disease-modifying antirheumatic drugs; CI, confidence interval; HR, hazard ratio; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; IR, incidence rate; TB, tuberculosis